Japan Abiomed Inc.
Basic information
- Head office
- 12th Floor, Muromachi Toho Mitsui Building, 2-2-1 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022, Japan
- Chief executive
- Hideyuki Yamamoto
- Capital
- 300,000,000 JPY (3 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
—
Network
History
Announced BVS 5000, the first left ventricular assist device approved by the US FDA for BTR (Bridge to Recovery).![]()
BVS 5000® becomes the first ventricular assist device ever approved by the U.S. FDA for bridge-to-recovery.![]()
Clinical use of the total replacement artificial heart AbioCor began, implanted in the first patient.![]()
Under new CEO Mike Minogue, Abiomed transitioned to products focused on heart recovery. AB5000 received FDA approval for BTR (Bridge to Recovery).![]()
Under new CEO Mike Minogue, Abiomed shifts focus to heart recovery; AB5000™ receives U.S. FDA approval for bridge-to-recovery.![]()
Acquired Impella CardioSystems based in Aachen, Germany. Impella obtained CE mark and began sales in Europe.![]()
Impella 2.5 heart pump receives U.S. FDA 510(k) clearance; Abiomed completes PROTECT I clinical trial.![]()
AB Portable Driver received FDA approval, and the first patient with AB5000 was discharged. Impella 5.0 and Impella LD (not approved in Japan) received FDA 510(k) clearance.![]()
Impella 5.0® and Impella LD® heart pumps receive U.S. FDA 510(k) clearance; AB Portable Driver receives U.S. FDA approval and the first patient is discharged on AB5000™.![]()
Launched the new Impella Controller (Automated Impella Controller). Achieved non-GAAP revenue. Results of RECOVER I clinical trial published in Journal of Thoracic and Cardiovascular Surgery.![]()
The new Automated Impella Controller™ (AIC) is now available; Abiomed achieves non-GAAP profitability; RECOVER I clinical trial results published in the Journal of Thoracic and Cardiovascular Surgery.![]()
Results of the PROTECT II randomized controlled trial published in Circulation. Impella CP received FDA 510(k) clearance. Abiomed co-founded MVPvets to support employment of veterans in the medical device industry.![]()
Results of the PROTECT II randomized controlled trial published in Circulation, the journal of the American Heart Association; Impella CP heart pump receives U.S. FDA 510(k) clearance; Abiomed co-founds MedTechVets.![]()
Started RECOVER RIGHT clinical trial for Impella RP (not approved in Japan) in the US. Established Japan Abiomed Inc.![]()
Abiomed announced acquisition of ECP, a medical device company based in Berlin, Germany. Over 20,000 patients treated with Impella.![]()
Abiomed announces the acquisition of ECP, a medical device company based in Berlin, Germany; Abiomed surpasses 20,000 patients supported with Impella![]()
All Impella products for left heart support received PMA approval for treatment of cardiogenic shock. Impella 2.5, Impella 5.0, and Impella Controller obtained medical approval in Japan. Impella CP received PMA for expanded indication for high-risk PCI in the US.![]()
Entire family of Abiomed Impella left side heart pumps receive U.S. FDA PMA approval; Impella 2.5® and Impella 5.0® receive regulatory approval in Japan; U.S. FDA grants expanded PMA approval to Impella CP® for high-risk PCI procedures![]()
New, expanded Abiomed headquarters officially opened in Duxbury, Massachusetts. Over 50,000 patients treated with Impella. First patient enrolled in STEMI DTU pilot randomized trial. FDA approved Impella RP (not approved in Japan) for right heart failure. Sales of Impella 2.5 and Impella 5.0 began in Japan.![]()
Abiomed celebrates the grand opening of its newly-expanded headquarters in Danvers, MA; surpasses 50,000 patients treated with Impella; first patient enrolls in STEMI DTU pilot randomized controlled trial; U.S. FDA grants PMA approval for Impella RP for right heart failure; physicians treat first patient with Impella in Japan![]()
The number of patients treated with Impella has exceeded 100,000 worldwide. The first patient was treated with Impella 5.5 SmartAssist in Germany. SmartAssist technology received regulatory approval from authorities. The US FDA approved the expansion of Impella's indication for use in high-risk PCI. Announced success of the STEMI DTU pilot randomized controlled trial.![]()
Abiomed surpasses 100,000 patients treated with Impella; German physicians treat first patient with Impella 5.5 with SmartAssist; SmartAssist technology receives regulatory approval; Abiomed launches Women's Initiative for Heart Recovery; U.S. FDA grants approval for expanded indications for Impella; investigators announce successful STEMI DTU pilot randomized controlled trial results![]()
The first patient was treated with Impella 5.5 SmartAssist in the United States. Sales of Impella CP began in Japan. The number of patients treated with Impella in Japan exceeded 1,000. The first patient was enrolled in the pivotal randomized controlled trial of STEMI DTU.![]()
First U.S. patients are treated with Impella 5.5 with SmartAssist; 1,000th patient treated with Impella in Japan; first patient enrolls in STEMI DTU™ pivotal randomized controlled trial![]()
Acquired Breethe's OXY-1 System and treated the first patient with ECMO technology (not approved in Japan, photo on the left). Treated the first patient with Impella ECP (not approved in Japan, photo on the right). The number of patients treated with Impella exceeded 150,000 worldwide. The US FDA granted EUA (Emergency Use Authorization) for Impella treatment in certain COVID-19 patients. The US FDA approved data streaming from Impella control devices, enabling AI algorithm analysis.![]()
Abiomed acquires Breethe™ and its OXY-1 System and treats first patients with ECMO technology; physicians treat first patients with the 9 French Impella ECP; Abiomed surpasses 150,000 patients treated with Impella; U.S. FDA grants EUA for Impella to provide therapy to certain COVID-19 patients; U.S. FDA approves data streaming from the Impella console![]()
The first patient was enrolled in the PROTECT IV randomized controlled trial. The number of patients treated with Impella exceeded 200,000. The US FDA designated Impella ECP, the world's smallest heart pump (not approved in Japan), as a Breakthrough Device. Impella RP with SmartAssist (not approved in Japan) received the highest level of approval from the US FDA for treatment of right heart failure. Abiomed acquired preCARDIA (not approved in Japan), which aims to improve prognosis in heart failure patients. Regulatory approval for Impella 5.5 SmartAssist was obtained in Japan.![]()
First patient enrolls in the PROTECT IV randomized controlled trial; Abiomed surpasses 200,000 patients treated with Impella; U.S. FDA grants breakthrough device designation to Impella ECP; U.S. FDA grants highest level of approval to Impella RP with SmartAssist; Abiomed acquires preCARDIA![]()
Abiomed acquired by Johnson & Johnson; Abiomed surpasses 250,000 patients treated with Impella; U.S. FDA grants 510(k) clearance for Impella Low Profile Sheath; Physicians treat the first patient with Impella BTR; All post-approval studies for Impella heart pumps completed successfully; Physicians treat first patient with Impella 5.5 in Japan![]()
Pivotal Impella ECP Study expands enrollment to three New Jersey hospitals; Analysis shows potential for more complete revascularizations with Impella during HRPCI; Reached 300,000+ patients treated globally![]()
A groundbreaking randomized controlled trial published in the New England Journal of Medicine demonstrated a mortality benefit from Impella use in AMICS shock due to STEMI; Celebrated 25 years of Impella and heart recovery; U.S. FDA expanded the usage of left-sided Impella devices to specific pediatric patients; Surpassed 350,000 patients treated globally![]()
News
There is no news.
Public records
National Tax Agency basic information9010001157532
- Trade name
- 日本アビオメッド株式会社
- Trade name (kana)
- ニホンアビオメッド
- Name in English
- Corporation type
- 301
- Address
- 〒103-0022 東京都中央区日本橋室町2丁目2番1号
- Postal code
- 1030022
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2019-03-28
- Change date
- 2016-10-17
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 2468552
METI gBizINFO9010001157532
- Corporate number
- 9010001157532
- Trade name
- 日本アビオメッド株式会社
- Trade name (kana)
- ニホンアビオメッド
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都千代田区西神田3丁目5番2号
- Postal code
- 1010065
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 千代田区
- City code
- 101
- Street address
- 西神田3丁目5番2号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役 山本 英右
- Capital
- Employees
- 126
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- E:製造業
- Date established
- 2013-12-10
- Unified government qualification - grade
- |B|B|
- Unified government qualification - business items
- 219|308
- Update date
- 2026-10-02
- Key information
- 9010001157532